Ken Griffin Ngm Biopharmaceuticals Inc Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.17 - $1.92 $315,924 - $518,440	270,021 Added 374.13%	342,195 $544,000
Q4 2023 Feb 14, 2024	SELL	$0.6 - $1.31 $55,183 - $120,483	-91,972 Reduced 56.03%	72,174 $62,000
Q3 2023 Nov 14, 2023	SELL	$1.05 - $3.37 $191,461 - $614,499	-182,344 Reduced 52.63%	164,146 $175,000
Q2 2023 Aug 14, 2023	BUY	$2.44 - $4.53 $656,606 - $1.22 Million	269,101 Added 347.73%	346,490 $897,000
Q1 2023 May 15, 2023	BUY	$3.72 - $5.4 $189,708 - $275,383	50,997 Added 193.23%	77,389 $315,000
Q4 2022 Feb 14, 2023	SELL	$3.41 - $12.93 $913,003 - $3.46 Million	-267,743 Reduced 91.03%	26,392 $132,000
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $836,152 - $1.17 Million	66,414 Added 29.16%	294,135 $3.85 Million
Q2 2022 Aug 15, 2022	BUY	$10.58 - $17.5 $739,838 - $1.22 Million	69,928 Added 44.32%	227,721 $2.92 Million
Q1 2022 May 16, 2022	SELL	$13.81 - $18.6 $7.41 Million - $9.98 Million	-536,354 Reduced 77.27%	157,793 $2.41 Million
Q4 2021 Feb 14, 2022	SELL	$17.26 - $22.02 $1.11 Million - $1.42 Million	-64,508 Reduced 8.5%	694,147 $12.3 Million
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $1.02 Million - $1.32 Million	50,576 Added 7.14%	758,655 $15.9 Million
Q2 2021 Aug 16, 2021	BUY	$15.06 - $30.03 $4.93 Million - $9.84 Million	327,650 Added 86.13%	708,079 $14 Million
Q1 2021 May 17, 2021	BUY	$24.99 - $31.93 $5.35 Million - $6.83 Million	214,036 Added 128.63%	380,429 $11.1 Million
Q4 2020 Feb 16, 2021	BUY	$16.21 - $31.44 $2.03 Million - $3.93 Million	125,036 Added 302.33%	166,393 $5.04 Million
Q3 2020 Nov 16, 2020	BUY	$15.59 - $19.97 $208,968 - $267,677	13,404 Added 47.95%	41,357 $658,000
Q2 2020 Aug 14, 2020	SELL	$11.97 - $23.47 $2.12 Million - $4.15 Million	-176,968 Reduced 86.36%	27,953 $551,000
Q1 2020 May 15, 2020	BUY	$10.0 - $19.51 $1.67 Million - $3.27 Million	167,388 Added 445.98%	204,921 $2.53 Million
Q4 2019 Feb 14, 2020	BUY	$9.97 - $20.28 $140,756 - $286,313	14,118 Added 60.29%	37,533 $694,000
Q3 2019 Nov 14, 2019	BUY	$13.09 - $18.19 $48,433 - $67,303	3,700 Added 18.77%	23,415 $324,000
Q2 2019 Aug 14, 2019	BUY	$12.56 - $16.6 $247,620 - $327,269	19,715 New	19,715 $289,000

Others Institutions Holding NGM

# of Institutions

Shares Held

2.6M

Call Options Held

300

Put Options Held

View Full List

About NGM BIOPHARMACEUTICALS INC

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

More about NGM

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account